HK1246276A1 - 斑蝥素和生物活性斑蝥素衍生物的商業上可行的合成 - Google Patents

斑蝥素和生物活性斑蝥素衍生物的商業上可行的合成

Info

Publication number
HK1246276A1
HK1246276A1 HK18105382.5A HK18105382A HK1246276A1 HK 1246276 A1 HK1246276 A1 HK 1246276A1 HK 18105382 A HK18105382 A HK 18105382A HK 1246276 A1 HK1246276 A1 HK 1246276A1
Authority
HK
Hong Kong
Prior art keywords
cantharidin
bioactive
derivatives
commercially viable
viable synthesis
Prior art date
Application number
HK18105382.5A
Other languages
English (en)
Inventor
Matthew Davidson
Steven R Schow
Original Assignee
Verrica Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56127857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1246276(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Verrica Pharmaceuticals Inc filed Critical Verrica Pharmaceuticals Inc
Publication of HK1246276A1 publication Critical patent/HK1246276A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D497/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D497/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Catalysts (AREA)
HK18105382.5A 2014-12-17 2018-04-25 斑蝥素和生物活性斑蝥素衍生物的商業上可行的合成 HK1246276A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462093396P 2014-12-17 2014-12-17
PCT/US2015/066487 WO2016100732A2 (en) 2014-12-17 2015-12-17 Commercially viable synthesis of cantharidin and bioactive cantharidin derivatives

Publications (1)

Publication Number Publication Date
HK1246276A1 true HK1246276A1 (zh) 2018-09-07

Family

ID=56127857

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18105382.5A HK1246276A1 (zh) 2014-12-17 2018-04-25 斑蝥素和生物活性斑蝥素衍生物的商業上可行的合成

Country Status (12)

Country Link
US (2) US10745413B2 (zh)
EP (1) EP3233865A4 (zh)
JP (3) JP6810693B2 (zh)
KR (1) KR102528106B1 (zh)
CN (2) CN114106013A (zh)
AU (2) AU2015364524A1 (zh)
BR (1) BR112017013029B1 (zh)
CA (1) CA2971279C (zh)
HK (1) HK1246276A1 (zh)
IL (2) IL252907B2 (zh)
MX (2) MX2017008097A (zh)
WO (1) WO2016100732A2 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102373297B1 (ko) 2013-08-21 2022-03-11 베리카 파마슈티컬스 인크. 피부 질병의 치료를 위한 조성물, 방법 및 시스템
WO2016100732A2 (en) 2014-12-17 2016-06-23 Verrica Pharmaceuticals, Inc. Commercially viable synthesis of cantharidin and bioactive cantharidin derivatives
EP3247996A4 (en) 2015-01-20 2019-01-02 Verrica Pharmaceuticals, Inc. Quantification and preparation of pharmaceutical grade cantharidin
CN106674248B (zh) * 2016-12-17 2019-02-26 重庆市中药研究院 一种斑蝥素的合成工艺
US11147790B2 (en) 2017-06-06 2021-10-19 Verrica Pharmaceuticals Inc. Treatment of cutaneous disorders
USD900312S1 (en) 2017-06-15 2020-10-27 Verrica Pharmaceuticals, Inc. Applicator
WO2019070980A2 (en) * 2017-10-04 2019-04-11 Verrica Pharmaceuticals, Inc. SYNTHESIS OF CANTHARIDINE
US20210393570A1 (en) * 2017-10-31 2021-12-23 Université de Bourgogne Therapeutical compositions for use in the treatment of non-malignant conditions associated with phosphatidylinositol-3-kinase activation: overgrowth spectrum, cutaneous capillary malformations and seborrheic keratoses
CN113455515A (zh) * 2021-06-24 2021-10-01 广东省农业科学院果树研究所 斑蝥素在制备防治柑橘采后绿霉菌的农药杀菌剂的应用
KR20240012182A (ko) 2022-07-20 2024-01-29 고려대학교 산학협력단 칸타리딘을 유효성분으로 포함하는 교모세포종 예방 또는 치료용 조성물

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4739621Y1 (zh) 1968-04-18 1972-11-30
US4148887A (en) 1977-06-13 1979-04-10 The Procter & Gamble Company Dermatological compositions
US4298752A (en) * 1980-09-19 1981-11-03 Regents Of The University Of California Cycloadduct precursors of cantharidin and method
US4895727A (en) 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
JP3117502B2 (ja) 1991-08-27 2000-12-18 株式会社資生堂 皮膚外用剤
JPH05255367A (ja) * 1992-02-28 1993-10-05 Jitsuei O カンタリジン誘導体組成物の製造法及びそれを含む抗ウイルス剤
US5445462A (en) 1993-08-03 1995-08-29 Medi-Flex Hospital Products, Inc. Liquid applicator
US5702694A (en) 1993-08-17 1997-12-30 Schering-Plough Healthcare Products, Inc. Compositions for treating corns, calluses and warts
US5590780A (en) 1995-06-22 1997-01-07 Wheaton Holding, Inc. Unit dose assembly
FR2754175B1 (fr) 1996-10-07 1999-07-02 Oreal Utilisation d'un organopolysiloxane de nature elastomerique associe a une phase organique dans un produit de demaquillage des ongles
US6030633A (en) 1998-05-18 2000-02-29 West Agro, Inc. Film-forming compositions for protecting animal skin
JPH11335303A (ja) 1998-05-26 1999-12-07 Lion Corp 苦味増強方法及び皮膚外用剤
US6337076B1 (en) 1999-11-17 2002-01-08 Sg Licensing Corporation Method and composition for the treatment of scars
US20030072814A1 (en) 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition for the treatment of warts
EP1390027B1 (en) * 2001-05-31 2008-04-02 The Chinese University Of Hong Kong Composition comprising demethylcantharidin in combination with platinum-containing anticancer agents and use thereof
US6899897B2 (en) 2001-06-18 2005-05-31 Jaleva, Inc. Gum resin as a carrier for topical application of pharmacologically active agents
US6673031B2 (en) 2001-09-25 2004-01-06 Phillip Mark Liquid applicator
ES2266564T3 (es) * 2001-10-19 2007-03-01 Isotechnika Inc. Sintesis de analogos de cicloporinas.
JP2004059446A (ja) * 2002-07-25 2004-02-26 Mitsui Chemicals Inc 脂環式化合物及びその製造方法
WO2004093786A2 (en) 2003-04-16 2004-11-04 Corium International Covalent and non-covalent crosslinking of hydrophilic polymers and adhesive compositions prepared therewith
US20050019418A1 (en) 2003-07-23 2005-01-27 Crutchfield Charles E. Wart treatment
US20070111954A1 (en) 2003-07-23 2007-05-17 Cuticeuticals, Inc. Apparatus and method of wart treatment
JP2005187330A (ja) 2003-12-24 2005-07-14 Lion Corp 歯牙貼布用製品及びゲル組成物の選定方法
FR2865360B1 (fr) 2004-01-22 2006-05-26 Oreal Applicateur comportant un element d'application solidaire, lors de l'utilisation, d'un recipient contenant un produit a appliquer
FR2872704B1 (fr) * 2004-07-12 2007-11-02 Laurent Schwartz Pluritherapie contre le cancer
US20060110415A1 (en) 2004-11-22 2006-05-25 Bioderm Research Topical Delivery System for Cosmetic and Pharmaceutical Agents
US20050111900A1 (en) 2004-11-30 2005-05-26 Francesca Fazzolari Ampoule and method of use
FR2885779B1 (fr) 2005-05-23 2007-08-10 Oreal Dispositif de conditionnement et d'application d'un produit cosmetique ou dermatologique
US20070187437A1 (en) 2006-02-10 2007-08-16 Nordson Corporation Dispensing tip for liquid dispensing systems and method of making the same
JP5132071B2 (ja) 2006-03-31 2013-01-30 小林製薬株式会社 皮膚外用剤
DE102006034272A1 (de) 2006-07-18 2008-01-24 Aesculap Ag & Co. Kg Flüssigkeitsspender in der Medizin in Form einer Handhabe sowie dessen Verwendung
CN100465176C (zh) 2006-08-18 2009-03-04 芜湖天远科技开发有限责任公司 一种提取斑蝥素的方法
US20080146674A1 (en) 2006-12-15 2008-06-19 Rosenberg E William Use of gentian violet in treatment of atopic dermatitis
US8518076B2 (en) 2007-01-08 2013-08-27 Advanced Medical Solutions (Plymouth) Limited Surgical adhesive applicator
CA2673166C (en) 2007-01-25 2015-09-22 Hyperbranch Medical Technology, Inc. Applicators for multiple component formulations and the like, and methods of use thereof
CN101036774B (zh) 2007-04-17 2010-12-29 贵州益佰制药股份有限公司 一种复方斑蝥口服制剂的检测方法
CN101108853B (zh) 2007-07-27 2010-05-26 贵州大学 斑蝥素分离纯化方法
CN100577665C (zh) * 2007-08-16 2010-01-06 广东药学院 一种抗肿瘤活性斑蛰素衍生物及其制备方法
DE102007046600A1 (de) 2007-09-27 2009-04-02 Linhardt Metallwarenfabrik Gmbh & Co Kg Verfahren zum Applizieren eines flüssigen, medizinischen Behandlungsmediums auf einen zu behandelden Bereich sowie Medizinprodukt
WO2009090495A2 (en) 2007-12-07 2009-07-23 Foamix Ltd. Oil and liquid silicone foamable carriers and formulations
JP5396125B2 (ja) 2009-03-30 2014-01-22 有限会社日本健康科学研究センター 被膜形成型製剤
WO2011044008A1 (en) 2009-10-08 2011-04-14 Schering-Plough Healthcare Products, Inc. Low ether composition and delivery apparatus
US20120016320A1 (en) 2010-07-13 2012-01-19 Lin Michael T Method and Device for Liquid Delivery
US20120148520A1 (en) 2010-12-10 2012-06-14 Michael Strobel Organic Iodine Complex Durable Barrier With Antimicrobial Preparations
FR2972928B1 (fr) 2011-03-25 2013-11-29 Urgo Lab Composition contenant une cellulose, une huile vegetale et un solvant volatil, ses utilisations comme pansement
US20120312709A1 (en) 2011-04-12 2012-12-13 Velcera, Inc. Device for storing and dispensing a medicament, and packaging for containing the same
CN102146086B (zh) 2011-04-12 2012-03-07 贵州金桥药业有限公司 一种斑蝥酸钠的制备方法
US9486829B2 (en) 2011-06-04 2016-11-08 Optmed, Inc. Applicator
CN102268006B (zh) 2011-06-15 2013-08-14 北京联合大学生物化学工程学院 一种复合酶提取斑蝥素的方法
US8871801B2 (en) 2011-08-01 2014-10-28 Jacob LEVITT Method of treating acquired perforating dermatosis with cantharidin
CN202920809U (zh) 2012-09-27 2013-05-08 合肥诚者成医药科技有限公司 一种治疗尖锐湿疣的软膏
US9463180B2 (en) 2013-03-14 2016-10-11 Quadex Pharmaceuticals, Llc Treatment of molluscum contagiosum
KR102373297B1 (ko) 2013-08-21 2022-03-11 베리카 파마슈티컬스 인크. 피부 질병의 치료를 위한 조성물, 방법 및 시스템
CN103923095A (zh) * 2014-04-23 2014-07-16 遵义医学院 一种去甲基斑蝥素酸钙
WO2016061193A1 (en) 2014-10-15 2016-04-21 Lixte Biotechnology, Inc. Process of synthesizing 3-(4-methylpiperazine-1-carbonyl)-7-oxabicyclo[2.2.1] heptane-2-carboxylic acid
WO2016100732A2 (en) 2014-12-17 2016-06-23 Verrica Pharmaceuticals, Inc. Commercially viable synthesis of cantharidin and bioactive cantharidin derivatives
EP3247996A4 (en) 2015-01-20 2019-01-02 Verrica Pharmaceuticals, Inc. Quantification and preparation of pharmaceutical grade cantharidin

Also Published As

Publication number Publication date
MX2017008097A (es) 2018-01-09
JP2021073173A (ja) 2021-05-13
IL252907B (en) 2020-06-30
CA2971279A1 (en) 2016-06-23
US20210070771A1 (en) 2021-03-11
US10745413B2 (en) 2020-08-18
CA2971279C (en) 2023-09-19
KR20170117027A (ko) 2017-10-20
JP6810693B2 (ja) 2021-01-06
BR112017013029A2 (pt) 2018-01-09
IL252907B2 (en) 2023-08-01
JP2018500336A (ja) 2018-01-11
WO2016100732A3 (en) 2016-09-09
WO2016100732A2 (en) 2016-06-23
CN107530322B (zh) 2021-10-15
KR102528106B1 (ko) 2023-05-03
AU2020244554B2 (en) 2022-10-20
US20190002474A1 (en) 2019-01-03
AU2020244554A1 (en) 2020-10-29
AU2015364524A1 (en) 2017-07-13
IL274968A (en) 2020-07-30
EP3233865A2 (en) 2017-10-25
JP2024037931A (ja) 2024-03-19
IL252907A0 (en) 2017-08-31
CN107530322A (zh) 2018-01-02
EP3233865A4 (en) 2018-12-05
MX2021010078A (es) 2021-09-21
CN114106013A (zh) 2022-03-01
BR112017013029B1 (pt) 2022-12-06

Similar Documents

Publication Publication Date Title
IL274968A (en) Commercially capable synthesis of cantharidin and biologically active cantharidin derivatives
IL248550A0 (en) History of indolin-2-one or pyrrolo-pyridin-2-one
PL3640486T3 (pl) Mebel
EP3157359A4 (en) Affecting enjoyment of food
GB201418739D0 (en) Bioprocess for corproduction of products
SI3154526T1 (sl) Trdne oblike sofosbuvira
PL3166860T3 (pl) Sztywne opakowanie do wyrobów do palenia
PT3113773T (pt) Formas cristalinas do grapiprant
IL246979A0 (en) Crystalline forms of sofosbuvir
RS64186B1 (sr) Upotreba vatrostalnih proizvoda
SG11201605915WA (en) Furo-3-carboxamide derivatives and methods of use
IL249348A0 (en) A new preparation and method for synthesis
HK1231395A1 (zh) 生物活性血紅素過氧化物酶組合物和使用方法
GB201404552D0 (en) Purification of dna-conjugate products
ZA201701976B (en) Synthesis of ent-progesterone and intermediates thereof
SG11201609739UA (en) Derivatives of dolaproine-dolaisoleuine peptides
IL249130B (en) Preparation of piperidine-4-carbothioamide
PL3174849T3 (pl) Synteza pochodnych pirolidyny
PL3131633T3 (pl) Pochodne MMF etylenoglikoli
IL249332A0 (en) Crystalline forms of sofosbuvir
HK1208220A1 (zh) 種 -烯丙基喜樹鹼衍生物的合成方法
GB201412359D0 (en) Composition of objects
GB201412089D0 (en) Composition of objects
TWM490224U (en) Structure of food
GB201406303D0 (en) Production of objects